A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
← catalyst calendarNCT06072482 · readout in 3,787 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
300estimated
Sites
83
Countries
Czechia, Denmark, Greece +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-07 | actual | When the study began enrolling |
| Primary completion | 2036-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
- Drug: Avacopan — also filed as CCX168
- Drug: Placebo
- Drug: Standard of Care
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
measured Up to Month 60
Percentage of Participants Experiencing Adverse Events of Special Interest
measured Up to Month 60
Percentage of Participants Experiencing Serious Adverse Events
measured Up to Month 60
Percentage of Participants Experiencing Adverse Events Leading to Withdrawal
measured Up to Month 60
Percentage of Participants Experiencing Adverse Events Leading to Death
measured Up to Month 60
Number of Participants Experiencing Clinical Significant Changes from Baseline in Vital Signs Measurements
measured Up to Month 60
Number of Participants Experiencing Clinical Significant Changes from Baseline in Hematology Assessments
measured Up to Month 60
Number of Participants Experiencing Clinical Significant Changes from Baseline in Serum Chemistry Assessments
measured Up to Month 60
Number of Participants Experiencing Clinical Significant Changes from Baseline in Urinalysis Assessments
measured Up to Month 60
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed